AlphAIalphai — Financial news for AI agents
SEC EDGARAUG 211 min read$KURA

Bair Teresa Brophy sold $398K of KURA

Bair Teresa Brophy (Chief Legal Officer) sold 31,487 shares of Kura Oncology, Inc. (KURA) at $12.63 ($0.40M total) on 2026-08-19 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Bair Teresa Brophy
Published Aug 21, 2026, 8:30 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 21, 2026, 8:50 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
alphai market briefInsider activity
Primary signal
$KURA
Bearish
medium confidence
Mentioned
$KURA
Relevance
3/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$KURABearishLow
01

Why it matters

The disclosure provides fresh data on insider holdings, useful for short-term traders.

02

Market read

Primary insider transaction; modest relevance for short-term price action.

03

What to watch

The insider retains a sizable stake, indicating continued confidence.

Relevance 3/10Novelty 6/10Timing: post-market 2026-08-19

Background

Kura Oncology filed a Form 4 reporting an insider sale under a 10b5-1 plan.

Company-level read

Ticker impact

$KURABearishMedium confidence
Context

Form 4 disclosed Chief Legal Officer sold 31,487 shares for $397,680, reducing her stake to 195,444 shares.

Expected impact

Possible modest downside pressure over the next few days.

Evidence & confidence

The sale size is modest relative to market cap, but insider sales often trigger short-term sell pressure.

Market effects

Sector

Minimal impact on the broader oncology biotech sector.

Regional

No significant regional effect.

Global

Limited to investors tracking insider activity.

Counterpoint

What could challenge this read

The sale could be a routine liquidity event, not a negative signal.

Key entities

  • Officer
    Bair Teresa Brophy

    Chief Legal Officer of Kura Oncology.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

KURA insider trading history →

Related articles

AUG 25
$KURAMed

Why is Kura Oncology stock surging today?

Kura Oncology's stock rose 11.6% in pre-market trading after CEO Troy Wilson bought 100,000 shares for $1.24 million, his second large purchase in a week. Analysts Citigroup and Jefferies reaffirmed positive ratings, citing strong commercial momentum for KOMZIFTI and Q2 earnings beat. The stock surpassed its 52-week high of $12.90.

investing.com2 min
AUG 19
$KURAHighAI 8/10

Kura Oncology (KURA) Q2 2026 Earnings Call Transcript

Kura Oncology (KURA) reported Q2 2026 earnings, with KOMZIFTI net product revenue up 57% QoQ to $9.1M. New patient starts increased 35% to 115, capturing majority market share in a specific leukemia segment. Total prescriptions rose 59% to 250. Cash decreased to $519M from $667.2M. Collaboration revenue guidance set at $45M-$55M for 2026. Net loss was $68.3M, up from $66.1M YoY. Clinical data showed strong results for ziftomenib and darlifarnib. Management expects pivotal trial results in 2028.

fool.com3 min
AUG 12
$KURAMed

Kura Oncology, Inc. (KURA): Results of Operations and Financial Condition

Kura Oncology, Inc. (KURA) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Kura Oncology Reports SECOND Quarter 2026 Financial Results – KOMZIFTI ® (ziftomenib) generated $9.1 million in net product revenue, up 57% over 1Q, and approximately 115 new patient starts, up 35% over 1Q – – KOMZIFTI ® achieved majority share of new patient starts

SEC EDGAR 8-K6 min